Molecular breast imaging: an emerging modality for breast cancer screening.
Molecular breast imaging: an emerging modality for breast cancer screening.
复制标题
DOI：
10.2217/bmt.14.49
复制
发表时间：
2015-01-01
影响因子：
0.7
通讯作者：
O'Connor MK
中科院分区：
文献类型：
--
作者：
O'Connor MK
筛查性乳房x线照相术被认为是一种不完美的成像工具，在乳腺组织致密的女性中表现不佳——这一限制推动了对补充筛查技术的需求。一种潜在的补充技术是分子乳腺成像（MBI）。伽马相机技术的重大改进使得MBI可以在低辐射剂量下进行，与断层合成和乳房x线照相术相当。最近一项针对乳腺组织致密的妇女的筛查试验显示，单独进行乳房x光检查的癌症检出率为每1000人中3.2人，而乳房x光检查和MBI相结合的癌症检出率为每1000人中12.0人。MBI的回忆率也低于乳房x光检查。MBI是一种很有前途的乳腺致密组织辅助筛查技术。
Screening mammography is recognized as an imperfect imaging tool that performs poorly in women with dense breast tissue – a limitation which has driven demand for supplemental screening techniques. One potential supplemental technique is molecular breast imaging (MBI). Significant improvements in gamma camera technology allow MBI to be performed at low radiation doses, comparable with those of tomosynthesis and mammography. A recent screening trial in women with dense breast tissue yielded a cancer detection rate of 3.2 per 1000 for mammography alone and 12.0 per 1000 for the combination of mammography and MBI. MBI also demonstrated a lower recall rate than that of mammography. MBI is a promising supplemental screening technique in women with dense breast tissue.